Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ophthalmic beta-blockers since timolol.

G D Novack

    Survey of Ophthalmology
    |March 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Newer topical beta-blockers for glaucoma show varied efficacy and safety profiles compared to timolol. This review aids ophthalmologists in evaluating these agents for elevated intraocular pressure.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ophthalmic drug delivery: development and regulatory considerations.

    Clinical pharmacology and therapeutics·2009
    Same author

    Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization.

    Journal of glaucoma·2001
    Same author

    Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2001
    Same author

    Submission of data sets to journals: what's the real issue?

    Archives of ophthalmology (Chicago, Ill. : 1960)·2000
    Same author

    Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.

    American journal of ophthalmology·2000
    Same author

    Financing new drug development in ophthalmology.

    Journal of glaucoma·2000

    Area of Science:

    • Ophthalmology
    • Pharmacology

    Background:

    • Topical timolol is the most common glaucoma medication, accounting for 70% of use.
    • Beta-blockers have been used for glaucoma treatment for two decades.

    Purpose of the Study:

    • To review newer topical beta-blockers for glaucoma treatment.
    • To evaluate the generalization that all ophthalmic beta-blockers are equivalent.
    • To aid ophthalmologists in assessing new agents.

    Main Methods:

    • Review of studies on topical beta-blockers for elevated intraocular pressure.
    • Inclusion of pharmacology and clinical trial design sections.
    • Focus on efficacy, duration, ocular toxicity, comfort, and systemic effects.

    Main Results:

    Related Experiment Videos

    • Newer beta-blockers are being evaluated against timolol.
    • Key assessment criteria include efficacy, duration, safety, and tolerability.
    • Pharmacology and trial design are crucial for evaluation.

    Conclusions:

    • Ophthalmologists must critically evaluate new beta-blockers.
    • Comparison with timolol is essential for efficacy and safety.
    • Individualized assessment is necessary for glaucoma management.